Onderneming Werewolf Therapeutics, Inc.
Aandelen
HOWL
US95075A1079
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
6,24 USD | -6,31% | -3,11% | +61,66% |
Vakgebied
Aantal werknemers: 47
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Cancer Therapeutics
100,0
%
| 16 | 100,0 % | 20 | 100,0 % | +21,60% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 16 | 100,0 % | 20 | 100,0 % | +21,60% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dan Hicklin
FOU | Founder | 60 | 19-10-17 |
Luke Evnin
FOU | Founder | 60 | 19-10-17 |
Timothy Trost
DFI | Director of Finance/CFO | 66 | 08-02-21 |
Chief Tech/Sci/R&D Officer | - | 15-06-21 | |
Randi Isaacs
CTO | Chief Tech/Sci/R&D Officer | 68 | 01-11-20 |
Ellen Lubman
IRC | Investor Relations Contact | 48 | 01-08-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Luke Evnin
FOU | Founder | 60 | 19-10-17 |
Dan Hicklin
FOU | Founder | 60 | 19-10-17 |
Michael Sherman
BRD | Director/Board Member | 58 | 27-05-21 |
Briggs Morrison
BRD | Director/Board Member | 65 | 01-11-19 |
Alon Lazarus
BRD | Director/Board Member | 49 | 01-08-19 |
Derek DiRocco
BRD | Director/Board Member | 43 | 01-12-20 |
Director/Board Member | - | 04/01 | |
Meeta Chatterjee
BRD | Director/Board Member | 69 | 28-10-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 43 347 363 | 40 623 740 ( 93,72 %) | 0 | 93,72 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+61,66% | 270 mln. | |
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |
- Beurs
- Aandelen
- Koers HOWL
- Onderneming Werewolf Therapeutics, Inc.